Profile data is unavailable for this security.
About the company
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
- Revenue in USD (TTM)80.89m
- Net income in USD-144.73m
- Incorporated2009
- Employees284.00
- LocationNurix Therapeutics Inc1700 Owens St Ste 205SAN FRANCISCO 94158-0006United StatesUSA
- Phone+1 (415) 660-5320
- Fax+1 (415) 525-4200
- Websitehttps://www.nurixtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyra Biosciences Inc | 0.00 | -75.45m | 863.23m | 49.00 | -- | 2.21 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Gyre Therapeutics Inc | 140.62m | -85.66m | 867.93m | 593.00 | -- | 15.31 | -- | 6.17 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 870.12m | 24.00 | -- | 3.87 | -- | 87,011.94 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Immunome Inc | 12.68m | -232.03m | 876.74m | 55.00 | -- | 3.06 | -- | 69.13 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Humacyte Inc | 0.00 | -105.70m | 891.94m | 183.00 | -- | 34.11 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| USANA Health Sciences, Inc. | 900.45m | 61.94m | 893.85m | 1.80k | 14.65 | 1.79 | 11.99 | 0.9927 | 3.20 | 3.20 | 46.56 | 26.25 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 898.66m | 309.00 | -- | 1.20 | -- | 25.44 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Ocular Therapeutix Inc | 59.84m | -115.27m | 918.49m | 267.00 | -- | 2.25 | -- | 15.35 | -1.09 | -1.09 | 0.6335 | 2.64 | 0.1793 | 2.23 | 2.51 | 224,127.30 | -34.54 | -46.70 | -37.58 | -54.18 | 90.99 | 89.36 | -192.62 | -228.65 | 21.29 | -9.10 | 0.1401 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 921.58m | 284.00 | -- | 4.53 | -- | 11.39 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 934.67m | 267.00 | -- | -- | -- | 2.26 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Liquidia Corp | 15.97m | -107.69m | 938.74m | 136.00 | -- | 10.87 | -- | 58.79 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| OPKO Health Inc | 799.60m | -252.43m | 947.91m | 3.93k | -- | 0.7567 | -- | 1.19 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| Innoviva Inc | 311.59m | 181.39m | 970.39m | 112.00 | 7.10 | 1.39 | 4.42 | 3.11 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 983.06m | 284.00 | -- | -- | -- | 23.63 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Data as of May 28 2024. Currency figures normalised to Nurix Therapeutics Inc's reporting currency: US Dollar USD
49.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Mar 2024 | 4.48m | 7.56% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 3.88m | 6.55% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.85m | 6.49% |
| Deep Track Capital LPas of 31 Mar 2024 | 3.00m | 5.05% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.73m | 4.60% |
| ARK Investment Management LLCas of 31 Mar 2024 | 2.64m | 4.44% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.55m | 4.30% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.36m | 3.97% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.13m | 3.60% |
| DWS Investments (UK) Ltd.as of 31 Mar 2024 | 1.50m | 2.53% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
